Editorial
The James Lind Alliance: an opportunity for neurologists in therapeutic research?
Consultant Neurologist, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; jwscadding@hotmail.com
| The first 150 words of the full text of this article appear below. |
|
The James Lind Alliance (JLA), launched just over a year ago, is named after the Scottish naval surgeon who conducted a randomised trial in scurvy, showing the superiority of citrus fruit over other treatments. The core aim of the JLA, which is a UK based organisation, is the proper involvement of patients, working together with clinicians (and not just doctors but nurses, therapists, and others), to identify important treatment uncertainties and to plan shared priorities in research (http://www.lindalliance.org).1 It was formed to address a number of shortcomings and problems in current therapeutic research.
There are mismatches between what researchers are researching and unanswered questions asked by patients and clinicians
Firstly, there are mismatches between what researchers are researching and unanswered questions asked by patients and clinicians; linked with this, there are mismatches between treatment outcomes studied by researchers and those regarded as important by patients. Doctors and patients
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
